Abstract
Data on the long-term outcomes in young patients after the Ross operation are limited and the question of the best pulmonary valve substitute remain elusive. This study aimed to assess the long-term outcomes in young patients who underwent the Ross operation with various pulmonary valve substitutes at a single institution. The retrospective study reviewed all patients (n = 112) who underwent the Ross operation at the University Hospital of Bordeaux, France between 2004 and 2020. Mean follow-up time was 4.2 years. Median age at operation was 15 years. Operative mortality was 0%. There were 1 late death (0,8%). Overall survival at 10 years was 99.2%. Freedom from the right ventricular outflow tract (RVOT) reoperation as better by the homograft compared to xenograft: 5.3 to 20% at 5 years and 5.3 and 65.7% at 10 years. The Ross procedure performed in young patients was associated with significative better freedom from RVOT reoperation with homograft compared with xenograft substitutes (P = 0,003).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
